5440-50-6

Upstream product

• 611-17-6 1-bromomethyl-2-chlorobenzene 
• 1068-90-2 2-acetylaminomalonic acid diethyl ester 
• 30412-43-2 sodium diethylacetamidomalonate 
• 611-19-8 1-chloro-2-(chloromethyl)benzene 
• 95-49-8 2-methylchlorobenzene 
• 105-53-3 diethyl malonate 

Downstream Products

• 14091-11-3 rac-2-chlorophenylalanine 
• 855650-84-9 acetylamino-(2-chloro-benzyl)-malonic acid 
• 120108-63-6 2-amino-3-(2-chlorophenyl)propionic acid hydrochloride 
• 856571-13-6 2-(2-aminobenzoylamino)-3-(2-chlorophenyl)propionic acid ethyl ester 
• 856571-32-9 3-(2-chlorophenyl)-2-{2-[(1H-indole-2-carbonyl)amino]benzoylamino}propionic acid ethyl ester 
• 103616-89-3 (2S)-2-amino-3-(2-chlorophenyl)propanoic acid 
• 103522-34-5 (S)-N-acetyl-o-chlorophenylalanine 
• 861054-40-2 N-[1-(2-chloro-benzyl)-2-oxo-propyl]-acetamide 
• 6955-12-0 (+/-)-N-acetyl-3-(2-chlorophenyl)alanine 

Relevant academic research and scientific papers

Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"

In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.

Ion channel modulating agents

The present invention relates to ion channel modulating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as modulators of SK Ca, IK Ca and BK Ca channels. In further aspects, the present invention relates to the use of these SK/IK/BK channel modulating agents for the manufacture of medicaments, for methods of therapy, and pharmaceutical compositions comprising the SK/IK/BK channel modulating agents. The SK/IK/BK channel modulating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK/BK channels.

Synthetic and biotransformation studies on prochiral non-proteinogenic amino acids: Diethyl α-acetamido, α-alkylmalonates

Nine diethyl α-acetamido, α-alkylmalonates 3-11 (alkyl=methyl, benzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2,6-difluorobenzyl, 3-trifluoromethylbenzyl, 4-trifluoromethylbenzyi, 2-chlorobenzyl and 3-chlorobenzyl) have been synthesised in three steps starting with diethyl malonate in overall yields of 49-90%. The structures of C-alkylated acetamidomalonates have been established on the basis of their speciral data, the structures of two compounds 9 and 11 are also confirmed on the basis of their X-ray crystallographic studies. Further, the X-ray crystal structure of the chiral monoethyl ester of α-acetamidomalonic acid 1 has been studied. None of our C-alkylated acetamidomalonate has been found to be a substrate for lipase-catalysed enantiodifferentiating deesterification/hydrolysis of the symmetric diester groups.

Enantioselective borane reduction of prochiral ketones catalyzed by a chloro-containing chiral β-amino alcohol

A chloro-containing chiral β-amino alcohol (S)-2-amino-3-(2-chlorophenyl)-1,1-diphenyl-1-propanol (1) was prepared from the related amino acid, which was synthesized via malonic ester method. As a catalyst for the enantioselective borane reduction of prochiral ketones, 1 is better than those that have a similar structure but have no halogen atom in the molecule.